Iovanace Biotherapeutics (IOVA) PT Lowered to $35 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts IOVA Hot Sheet
Price: $8.83 --0%
Rating Summary:
9 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
9 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Piper Sandler analyst Joseph Catanzaro lowered the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $35.00 (from $45.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Iovanace Biotherapeutics (IOVA) PT Raised to $8 at UBS
- Iovance reports 24.6% response rate in lung cancer TIL therapy trial
- Keurig Dr Pepper (KDP) PT Raised to $42 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
